Are Biologics the Wave of the Future?

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Still Time to Jump On the Bandwagon
• The Worldwide Biologics Landscape
  • Few Biologics Players Dominate
    • Amgen' s Reign as Biologics King
    • Genentech' s Very Successful Ride with Roche
    • Johnson & Johnson' s Profi ts from Early Biologics Acquisition
    • Novo Nordisk
  • Big Pharma' s Lack of Early Interest
• Biologics Are Booming- Especially MAbs
  • New Molecular Entities
  • Specialized and Niche Markets
  • MAbs Are Driving Extraordinary Growth
  • Biologics Development Pipelines
• Deal Mania- Ante Up
  • Recent Biologics Converts
    • AstraZeneca
    • GlaxoSmithKline
    • Novartis
    • Pfizer
  • Anything MAb Is on the Auction Block
  • Big Buyouts Through Mergers and Acquisitions
    • Bayer Schering Pharma
    • Merck Serono
    • GlaxoSmithKline Acquires Domantis
    • Amgen Acquires Abgenix
    • AstraZeneca Acquires Cambridge Antibody Technology
    • Merck & Co. Acquires Abmaxis
  • Glycoengineering Is Really Hot
• Biologics Pricing and Cost-Effectiveness
  • Price Comparisons
  • The Cost of Developing Biologics
  • Cost-Effectiveness and Drug Reimbursement
• Biogenerics
  • Regulatory Environment
  • Biogenerics Pricing
  • Biogenerics Market Dynamics
• Outlook

Tables:

• 1. Major Biologics Companies: 2005 Sales and Projected 2012 Sales of Key Biologic Products
• 2. Select Biologics Under Development, March 2007
• 3. Acquisitions and License Agreements for Late-Stage Biologics, 2005 and 2006
• 4. Recent Acquisitions of Biotechnology Companies with Biologics Optimization Technologies
• 5. Cost-Effectiveness of Select Biologics

Figures:

• 1. The 100 Best-Selling Pharmaceutical Products Worldwide, By Technology, 2006
• 2. Best-Selling Biologics Worldwide, 2006
• 3. Approvals of New Biopharmaceutical Products in the United States, 1990 Through October 2006
• 4. Projected Growth in Biologics Sales, 2001-2010
• 5. Average Prices of Leading Biologics, Small-Molecule Drugs, and Pharmaceuticals Overall in the Major Markets as a Percentage of U.S. Prices
• 6. Total Capitalized Cost per Approved Biopharmaceutical, 2006
• 7. Biogenerics Market Dynamics, 2005-2015